Naveena Singh
MD, FRCPath, FRCPC
Dr. Singh is a gynecological histopathologist who has devoted a large part of her career to improving reporting standards in diagnostic histopathology through teaching, research, participation in expert committees and co-authorship of guidelines, textbooks, chapters and review articles. She has been the meetings secretary (2007-2012) and President (2016-2019) of the British Association of Gynaecological Pathologists, and is currently co-Chair of the Education Committee of the International Society of Gynecological Pathologists. In these roles and otherwise, she has carried out several national and international collaborative research and quality projects, and facilitated development of educational material on a range of topics provided through the websites (www.thebagp.org and www.isgyp.ca). She has been an invited member of national and international expert committees, such as the European Society of Medical Oncology (ESMO; guidance for clinical management of ovarian cancer, 2018; guidance on microsatellite instability testing for immunotherapy in cancer, 2019), World Health Organization Classification of Female Genital Tumours (WHO; lead and co-author, multiple chapters including endometrial cancer, 2020) and the International Collaboration in Cancer Reporting.
In recent years she has devoted her attention to overcoming barriers to implementing molecular classification of endometrial carcinoma into routine diagnostic practice: knowledge translation, accurate immunohistochemistry interpretation and development of surrogate tests for next generation sequencing. In 2021-2022, she led a successful application to make POLE testing accessible to all endometrial cancer patients within England, alongside a testing algorithm endorsed by the British Gynaecological Cancer Society.
